Smolinski Stephen 4
4 · Avalo Therapeutics, Inc. · Filed Jan 6, 2022
Insider Transaction Report
Form 4
Smolinski Stephen
Chief Commercial Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-01-04+400,000→ 400,000 totalExercise: $1.70Exp: 2032-01-04→ Common Stock (400,000 underlying)
Footnotes (1)
- [F1]The stock option will vest over four years, with the first 25% vesting on the first anniversary of the grant date, and the remainder vesting in equal monthly installments over the following 36 months, subject to the reporting person's continued service on each such vesting date.